Published in J Biol Chem on December 24, 1999
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol (2004) 1.91
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A (2005) 1.89
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron (2010) 1.75
Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci (2014) 1.66
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol (2003) 1.64
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem (2007) 1.47
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal (2008) 1.47
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.46
Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. Cancer Res (2016) 1.41
Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol (2005) 1.40
Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep (2000) 1.32
Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J (2005) 1.27
Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol (2003) 1.24
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol (2008) 1.07
The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol (2003) 1.07
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem (2010) 1.03
ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol (2004) 1.03
Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem (2009) 1.01
A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene (2011) 1.00
Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res (2009) 0.99
Receptor-interacting protein 140 is a repressor of the androgen receptor activity. Mol Endocrinol (2006) 0.99
The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol (2012) 0.98
Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem (2010) 0.97
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett (2011) 0.93
Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK. EMBO J (2002) 0.92
Novel ATPase of SNF2-like protein family interacts with androgen receptor and modulates androgen-dependent transcription. Mol Biol Cell (2002) 0.91
Structural features discriminate androgen receptor N/C terminal and coactivator interactions. Mol Cell Endocrinol (2011) 0.90
Visualising androgen receptor activity in male and female mice. PLoS One (2013) 0.89
A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem (2012) 0.88
Direct interdomain interactions can mediate allosterism in the thyroid receptor. J Biol Chem (2009) 0.87
Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J Biol Chem (2012) 0.87
The Drosophila juvenile hormone receptor candidates methoprene-tolerant (MET) and germ cell-expressed (GCE) utilize a conserved LIXXL motif to bind the FTZ-F1 nuclear receptor. J Biol Chem (2012) 0.87
Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain. Mol Endocrinol (2009) 0.85
Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation. J Biol Chem (2012) 0.85
Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor. Mol Endocrinol (2009) 0.85
Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol (2013) 0.84
Hormone binding and co-regulator binding to the glucocorticoid receptor are allosterically coupled. J Biol Chem (2010) 0.82
Analysis of interdomain interactions of the androgen receptor. Methods Mol Biol (2011) 0.82
Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One (2014) 0.82
Is GSN significant for hip BMD in female Caucasians? Bone (2014) 0.82
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci (2016) 0.81
Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets (2013) 0.80
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor. J Biol Chem (2011) 0.80
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol (2013) 0.78
Current status of treatment of spinal and bulbar muscular atrophy. Neural Plast (2012) 0.78
Polyglutamine androgen receptor-mediated neuromuscular disease. Cell Mol Life Sci (2016) 0.77
Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell Endocrinol (2013) 0.77
Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA. Cell Rep (2015) 0.76
Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget (2014) 0.76
Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene (2016) 0.75
Trinucleotide repeats and protein folding and disease: the perspective from studies with the androgen receptor. Future Sci OA (2015) 0.75
Androgen receptor regulation by histone Methyltransferase suppressor of variegation 3-9 homolog 2 and melanoma antigen-A11. Mol Cell Endocrinol (2016) 0.75
A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations. Int J Mol Sci (2017) 0.75
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature (1995) 6.33
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature (1995) 5.40
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J (1990) 5.05
TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J (1996) 4.96
Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature (1995) 4.79
The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J (1995) 4.72
A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol (1996) 4.69
Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev (1995) 4.22
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J (1998) 3.64
Steroid hormone receptors compete for factors that mediate their enhancer function. Cell (1989) 3.50
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science (1988) 3.40
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol (1998) 3.08
The promise of retinoids to fight against cancer. Nat Rev Cancer (2001) 2.92
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem (2000) 2.58
Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J (1996) 2.47
The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature (1988) 2.47
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med (2001) 2.41
The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol (1988) 2.36
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell (2000) 2.33
Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A (1989) 2.28
The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res (1989) 2.05
Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. Blood (1977) 2.05
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J (1990) 1.90
Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J (1992) 1.88
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. Virology (1991) 1.86
Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol (1995) 1.83
Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci (2000) 1.77
Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci U S A (1988) 1.76
Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet (1989) 1.74
Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem (1992) 1.73
The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificites of the DNA binding domains. EMBO J (1993) 1.72
RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J (1995) 1.58
Two distinct actions of retinoid-receptor ligands. Nature (1996) 1.55
Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem (1995) 1.54
Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol (2000) 1.53
Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol (1997) 1.53
Insulin-like growth factor-mediated muscle differentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J Biol Chem (2001) 1.51
Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem (1998) 1.48
The androgen receptor: an overview. Recent Prog Horm Res (1994) 1.48
Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements. EMBO J (1994) 1.46
Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem (1995) 1.45
Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol (1995) 1.41
Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol (1990) 1.40
Hormone-dependent transactivation by the human androgen receptor is regulated by a dnaJ protein. J Biol Chem (1995) 1.39
A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol (1991) 1.39
Localization of ecdysterone on polytene chromosomes of Drosophila melanogaster. Proc Natl Acad Sci U S A (1980) 1.38
A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat. J Biol Chem (1990) 1.37
Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM. Oncogene (2006) 1.37
Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol (1999) 1.32
Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep (2000) 1.32
Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. J Mol Med (Berl) (1997) 1.31
A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J (1997) 1.30
Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat Struct Biol (1998) 1.29
In vivo targeted mutagenesis of a regulatory element required for positioning the Hoxd-11 and Hoxd-10 expression boundaries. Genes Dev (1996) 1.29
Cloning of the chicken progesterone receptor. Proc Natl Acad Sci U S A (1986) 1.29
Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem (1993) 1.27
Nuclear receptors in cell life and death. Trends Endocrinol Metab (2001) 1.26
Efficient transactivation by retinoic acid receptors in yeast requires retinoid X receptors. Proc Natl Acad Sci U S A (1993) 1.25
Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology (1990) 1.23
Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem (1997) 1.23
Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J (1991) 1.22
Widely spaced, directly repeated PuGGTCA elements act as promiscuous enhancers for different classes of nuclear receptors. Mol Cell Biol (1995) 1.20
Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem (1976) 1.20
Complete androgen insensitivity due to deletion of exon C of the androgen receptor gene highlights the functional importance of the second zinc finger of the androgen receptor in vivo. Mol Endocrinol (1992) 1.20
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem (1997) 1.20
Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. J Clin Endocrinol Metab (1999) 1.19
A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. J Biol Chem (1992) 1.19
Expression of active hormone and DNA-binding domains of the chicken progesterone receptor in E. coli. EMBO J (1989) 1.19
Towards novel paradigms for cancer therapy. Oncogene (2010) 1.18
Ligand-independent oligomerization of natriuretic peptide receptors. Identification of heteromeric receptors and a dominant negative mutant. J Biol Chem (1992) 1.17
Retinoid X receptor alpha forms tetramers in solution. Proc Natl Acad Sci U S A (1995) 1.17
Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol (1996) 1.17
Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. J Biol Chem (2001) 1.17
Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol (2004) 1.16
EMS Agenda for the Future: where we are...where we want to be. Prehosp Emerg Care (1998) 1.16
Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology (1999) 1.16
Pure and functionally homogeneous recombinant retinoid X receptor. J Biol Chem (1994) 1.15
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A (1989) 1.13
The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol (1988) 1.13
A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol (1996) 1.12
A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science (1992) 1.10
Response elements of the androgen-regulated C3 gene. J Biol Chem (1992) 1.10
The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol (2001) 1.08
EMS agenda for the future: where we are ... where we want to be. EMS Agenda for the Future Steering Committee. Ann Emerg Med (1998) 1.07
Zinc potentiation of androgen receptor binding to nuclei in vitro. Biochemistry (1984) 1.06